Sertraline Hydrochloride Patent Expiration
Sertraline Hydrochloride is Used for treating disorders of the serotonergic system such as depression and anxiety-related disorders. It was first introduced by Viatris Specialty Llc
Sertraline Hydrochloride Patents
Given below is the list of patents protecting Sertraline Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zoloft |
US6727283 (Pediatric) | Sertraline oral concentrate |
Apr 11, 2020
(Expired) | Viatris |
| Zoloft |
US7067555 (Pediatric) | Sertraline oral concentrate |
Apr 11, 2020
(Expired) | Viatris |
| Zoloft | US6727283 | Sertraline oral concentrate |
Oct 11, 2019
(Expired) | Viatris |
| Zoloft | US7067555 | Sertraline oral concentrate |
Oct 11, 2019
(Expired) | Viatris |
| Zoloft |
US5248699 (Pediatric) | Sertraline polymorph |
Feb 13, 2013
(Expired) | Viatris |
| Zoloft | US5248699 | Sertraline polymorph |
Aug 13, 2012
(Expired) | Viatris |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Sertraline Hydrochloride's patents.
Latest Legal Activities on Sertraline Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Sertraline Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Nov, 2017 | US7067555 |
| Patent Issue Date Used in PTA Calculation Critical
| 27 Jun, 2006 | US7067555 |
| Recordation of Patent Grant Mailed Critical
| 27 Jun, 2006 | US7067555 |
| Issue Notification Mailed Critical
| 07 Jun, 2006 | US7067555 |
| Dispatch to FDC | 01 Jun, 2006 | US7067555 |
| Application Is Considered Ready for Issue Critical
| 04 May, 2006 | US7067555 |
| Mail Examiner's Amendment | 17 Apr, 2006 | US7067555 |
| Pubs Case Remand to TC Critical
| 13 Jan, 2006 | US7067555 |
| Issue Fee Payment Received Critical
| 07 Nov, 2005 | US7067555 |
| Issue Fee Payment Verified Critical
| 07 Nov, 2005 | US7067555 |
Sertraline Hydrochloride's Family Patents
